Seres Therapeutics, Inc. (MCRB) Operating cash flow 2016–2025
Seres Therapeutics, Inc. (MCRB) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$1.1MFY2025 · since FY2016: $43.9M → $1.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.1M | +100.8% |
| FY2024 | -$148.6M | -26.6% |
| FY2023 | -$117.4M | +48.7% |
| FY2022 | -$228.8M | -3521.3% |
| FY2021 | $6.7M | +107.1% |
| FY2020 | -$93.6M | -22.3% |
| FY2019 | -$76.5M | -21.7% |
| FY2018 | -$62.9M | +16.8% |
| FY2017 | -$75.5M | -272.0% |
| FY2016 | $43.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MCRB financial trends
MCRB RevenueMCRB Net incomeMCRB Net marginMCRB Gross profitMCRB Gross marginMCRB Operating incomeMCRB Operating marginMCRB Free cash flowMCRB Capital expendituresMCRB Return on equityMCRB Stock buybacksMCRB Dividends paidMCRB Total assetsMCRB Total liabilitiesMCRB Shareholders’ equityMCRB overview →